T7噬菌体转运真核表达载体入胞表达平台的构建

[目的]构建携带锚定序列的真核表达载体,研究T7噬菌体识别、包裹和转运真核表达载体进入细胞实现蛋白表达的可行性,为DNA疫苗研发建立新的技术平台.[方法]本研究通过重叠延伸PCR方法获得候选锚定序列并插入真核表达载体;建立荧光定量PCR方法比较T7噬菌体识别、包裹真核表达载体的效率;激光共聚焦显微镜观察T7噬菌体转运真...     

利用细胞筛选法从噬菌体抗体库鉴定人源HIV-1单克隆中和抗体

以细胞法从HIV-1CRF07_BC特异性噬菌体抗体库中筛选和鉴定针对病毒包膜蛋白(Envelope,Env)的人源单克隆中和抗体。将pCH064.2-Env质粒转染293T细胞,以表达Env的活细胞淘洗噬菌体抗体库;利用细胞ELISA方法筛选Env特异性噬菌体阳性克隆,并测定抗体重链可变区(VH)和轻链可变区(VL)序列;以Ni+2-NTA层析柱纯化抗体Fab,SDS-PAGE分析抗体纯度;采用基于转染细胞和重组蛋白的ELISA以及流式细胞技术分析抗体的结合活性;以HIV-1假病毒系统评价抗体的中和活性。四轮淘洗使细胞特异性噬菌体得到约650倍的高度富集,细胞ELISA筛选到28个抗HIV Env的阳性克隆,序列分析发现五个具有不同VH和VL序列的抗体Fab(2801、2837、2863、2870和2920)。这些抗体与转染env的293T细胞反应,但不与重组表达的可溶性gp120蛋白反应,说明它们有可能针对依赖于Env复合物的空间构象表位。我们发现2801、2863和2870三个Fab抗体对HIV-1CRF07_BC亚型CH120.6毒株具有较强的中和活性,其IC50值分别为2.24μg/mL、0.89μg/mL和3.09μg/mL。其中,2801和2863对B亚型HIV-1毒株SF162具有较强的交叉中和作用,其IC50值分别为0.69μg/mL和3.52μg/mL。提示表达于293T细胞表面的HIV-1 Env可以有效富集和筛选噬菌体抗体库,并能成功分离和鉴定依赖于Env空间构象表位的HIV-1中和抗体。因此本研究为探讨HIV-1中和抗体的反应机制和研发艾滋病疫苗提供了新的技术平台。     

T7启动子在哺乳类动物细胞中启动外源基因表达的研究

人低密度脂蛋白（LDL）受体基因cDNA和氯霉素已酞转移酶基因（CAT）及PolyA信号序列被克隆进pGEM4载体的T7噬茵体启动子下游,构建成质粒pT7LDLR和pT7CAT．两个重组质粒转化CHO细胞．PCR和CAT酶实验显示：两个基因被T7噬菌体启动子所启动．结果证实真核生物RNA聚合酶能够识别T7启动子,转录外源基因．常用的含有T7启动子的质粒可同时作为原核生物和真核生物的表达载体．     

噬菌体T7溶菌酶基因的克隆

以Pbr322及含有噬菌体T7 RNA聚合酶强启动子φ10的Pbr322衍生物作为克隆载体,经限制内切酶AvaⅡ+HaeⅢ切割的一段噬菌体T7 DNA片段分别克隆到Pbr322及其衍生质粒的BamHⅠ位点上。插入的DNA片段为632碱基对。该片段包括噬菌体T7基因3．5和T7 RNA聚合酶弱启动子φ3．8的全部编码序列。已知噬菌体T7基因3．5的功能为产生噬菌体T7溶菌酶,利用氯仿处理检测带有重组质粒的转化子胞内溶菌酶活力。证明两种克隆株整体细胞中,均有溶菌酶存在。用10一20％SDS-聚丙烯酰胺凝肢电泳检查噬菌体T7基因3．5蛋白带,结果表明T7基因3．5在Pbr322衍生质粒中的表达优于Pbr322。     

高效抗细菌植物表达载体的构建

噬菌体T7 DNA用AvaⅡ酶解后,PCR扩增获得T7溶菌酶基因.DNA序列分析表明,T7溶菌酶基因的核苷酸序列与国外发表的序列有99.5%的同源性,推测的氨基酸序列完全一致.又用PCR法改造了克隆于pUC19中的烟草病原相关蛋白1b(PR-1b)的信号肽基因和抗菌肽Shiva-Ⅰ基因,将信号肽基因分别融合于T7溶菌酶基因和Shiva-Ⅰ基因的5’末端,并将两个融合基因分别置于一个植物表达载体中的两个表达框架内,以使转基因植物中T7溶菌酶基因和Shiva-Ⅰ基因同时表达且表达产物可分泌到细胞外.本工作为用植物基因工程方法培育抗细菌转基因作物打下了基础.     

噬菌体肽库筛选抗人B7-H4中和抗体的模拟抗原表位及其免疫原性鉴定

目的:用噬菌体呈现随机12肽库筛选能与抗人B7-H4(h B7-H4)中和抗体特异性结合的模拟抗原表位肽,并用其免疫小鼠检测其免疫原性。方法:以抗h B7-H4中和抗体为靶分子,用体外生物淘洗法从噬菌体呈现随机12肽库中筛选与之结合的噬菌体克隆,用竞争性细胞ELISA鉴定阳性噬菌体克隆;化学合成候选多肽,并与钥孔血蓝蛋白或破伤风毒素偶联鉴定多肽的特异性;进一步用融合蛋白免疫小鼠检测其免疫原性和抗血清的补体依赖的细胞杀伤活性(CDC)。结果:经过3轮体外筛选后随机挑取50个阳性噬菌体克隆,其中20个克隆与抗h B7-H4抗体有较强的结合能力,DNA测序得到6组结构相似的肽序列;竞争性ELISA结果显示1号肽噬菌体能与细胞表面的h B7-H4竞争性地结合抗h B7-H4单抗;点杂交结果显示1号肽能特异性结合抗h B7-H4单抗;小鼠免疫实验结果显示1号肽融合蛋白能诱导高滴度的抗h B7-H4抗血清,并且抗血清具有补体依赖的细胞杀伤活性。结论:筛选得到能与抗h B7-H4中和抗体特异性结合的12肽模拟抗原表位序列并且具有免疫原性,为进一步开发h B7-H4相关的多肽疫苗提供了实验依据。     

A型禽流感病毒M2e重组T7噬菌体疫苗构建及免疫原性研究

构建展示A型禽流感病毒M2e多肽的重组T7噬菌体,检测其对SPF鸡的免疫保护效果。比对GenBank近期发表的A型禽流感病毒M2e基因序列进行人工合成并重复至两拷贝,将其克隆到T7Select 415-1b噬菌体多克隆位点,构建重组噬菌体T7-M2e。经PCR鉴定并序列测定筛选阳性重组噬菌体,SDS-PAGE和Westernblot检测重组噬菌体表面M2e多肽。重组噬菌体以1×1010pfu/只剂量免疫SPF鸡,免疫后不同时间段采血通过ELSIA检测血清中抗M2e抗体,免疫荧光检测血清抗体与H9亚型禽流感病毒的结合能力,并以200个EID50/只剂量进行攻毒保护效率检测。成功构建重组噬菌体T7-M2e,插入两拷贝M2e基因获得表面展示,并与M2e抗体有免疫反应活性。噬菌体疫苗免疫后均产生抗M2e抗体,其抗血清能跟病毒粒子特异性结合,攻毒保护率达4/5(80%)。获得了展示禽流感病毒M2e多肽的重组噬菌体,噬菌体疫苗免疫鸡产生较高血清抗体并提供攻毒保护,为新型通用禽流感疫苗研制提供新思路。     

抗鳗弧菌独特型单克隆抗体dsFv的构建及其噬菌体表面呈现

抗鳗弧菌独特型单克隆抗体 1E10是能够模拟鳗弧菌的保护性表位 ,可以作为疫苗使用的一种单克隆抗体 .利用基因工程抗体技术从抗鳗弧菌独特型单克隆抗体杂交瘤细胞株 1E10中克隆出抗体的重链及轻链可变区基因 (VH 和VL) .通过定点突变技术将VH4 4和VL10 5突变为半胱氨酸并且连接到噬菌体表达载体pCANTAB5E中 ,突变后的VH 和VL 基因位于cpⅢ先导序列和cpⅢ基因之间 ,在LacZ启动子调控之下 ,以融合蛋白的形式被导入细胞间隙 ,依靠链间二硫键组装成二硫键稳定型Fv抗体 (dsFv) .加入辅助噬菌体M13K0 7后 ,dsFv以融合蛋白的形式表达在噬菌体表面 .ELISA测定显示 :dsFv噬菌体能够与抗原结合并且这种结合呈噬菌体浓度依赖 .结果表明 :成功构建出了抗鳗弧菌独特型单克隆抗体dsFv基因并使其在噬菌体表面获得了正确呈现 .该dsFv噬菌体有望成为新一代基因工程疫苗用于预防鱼类鳗弧菌感染     

用噬菌体随机肽库筛选SARS冠状病毒S蛋白单克隆抗体2C5的模拟表位

SARS-CoVS蛋白特异的单克隆抗体2C5具有病毒中和作用。以单克隆抗体2C5为筛选靶分子,筛选噬菌体展示随机7肽库。经三轮淘洗后随机挑选20个噬菌体克隆进行ELISA分析和序列测定。在10个ELISAOD值大于0.2的阳性噬菌体克隆中,有8个噬菌体克隆展示有共同的7肽序列TPEQQFT。展示有该序列的噬菌体克隆能竞争抑制SARS-CoVS蛋白抗原与单抗2C5的结合。结果表明TPEQQFT为单克隆抗体2C5的模拟表位。该结果可对进一步研究S蛋白结构与功能和设计SARS疫苗有一定的参考意义。     

利用金属离子(Fe3+)配体层析亲和筛选蛋白激酶识别的底物序列

将cAMP依赖的蛋白激酶(cAPK)识别的特征底物序列与噬菌体外膜蛋白g3p融合,展示于线状噬菌体fd的表面,构建了cAPK底物(PKS)噬菌体.噬菌体体外磷酸化标记结果表明,PKS噬菌体上分子量约为60ku的蛋白可被明显磷酸化标记,与PKS-g3p融合蛋白的分子量一致.利用金属离子(Fe³⁺)配体树脂亲和筛选经cAPK磷酸化标记的Phage display随机15肽库,4轮筛选后挑取单克隆进行DNA序列测定,确定展示于噬菌体表面的多肽序列.结果表明,在所挑选的14个克隆中有5个克隆具有典型的cAPK磷酸化序列特征(R)RXS/T.对这些噬菌体的体外磷酸化标记实验结果显示,其中有(R)RXS/T序列特征的噬菌体可在分子量约60ku处被特征性磷酸化标记,与PKS噬菌体的磷酸化标记特征一致;其他有一些不具备(R)RXS/T序列特征的噬菌体也可被特征性磷酸化.     

Induction of Protective Anti-CTL Epitope Responses against HER-2-Positive Breast Cancer Based on Multivalent T7 Phage Nanoparticles

We report here the development of multivalent T7 bacteriophage nanoparticles displaying an immunodominant H-2k^d-restricted CTL epitope derived from the rat HER2/neu oncoprotein. The immunotherapeutic potential of the chimeric T7 nanoparticles as anti-cancer vaccine was investigated in BALB/c mice in an implantable breast tumor model. The results showed that T7 phage nanoparticles confer a high immunogenicity to the HER-2-derived minimal CTL epitope, as shown by inducing robust CTL responses. Furthermore, the chimeric nanoparticles protected mice against HER-2-positive tumor challenge in both prophylactic and therapeutic setting. In conclusion, these results suggest that CTL epitope-carrying T7 phage nanoparticles might be a promising approach for development of T cell epitope-based cancer vaccines.     

Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems

Background

Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors. In this study, we have designed a therapeutic vaccine based on chitosan nanodelivery systems to deliver HPV-16 E7 DNA vaccine, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer. We have developed a Nano-chitosan (NCS) as a carrier system for intramuscular administration using a recombinant DNA vaccine expressing HPV-16 E7 (NCS-DNA E7 vaccine). NCS were characterized in vitro for their gene transfection ability.

Results

The transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent proteins was well observed. In addition, NCS-DNA E7 vaccine induced the strongest E7-specific CD8+ T cell and interferon γ responses in C57BL/6 mice. Mice vaccinated with NCS-DNA E7 vaccine were able to generate potent protective and therapeutic antitumor effects against challenge with E7-expressing tumor cell line, TC-1.

Conclusions

The strong therapeutic effect induced by the Chitosan-based nanodelivery suggest that nanoparticles may be an efficient carrier to improve the immunogenicity of DNA vaccination upon intramuscular administration and the platform could be further exploited as a potential cancer vaccine candidate in humans.     

Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors.

Initial attempts to clone the matrix (M) gene of vesicular stomatitis virus (VSV) in a vaccinia virus expression vector failed, apparently because the expressed M protein, and particularly a carboxy-terminus-distal two-thirds fragment, was lethal for the virus recombinant. Therefore, a transient eucaryotic expression system was used in which a cDNA clone of the VSV M protein mRNA was inserted into a region of plasmid pTF7 flanked by the promoter and terminator sequences for the T7 bacteriophage RNA polymerase. When CV-1 cells infected with recombinant vaccinia virus vTF1-6,2 expressing the T7 RNA polymerase were transfected with pTF7-M3, the cells produced considerable amounts of M protein reactive by Western blot (immunoblot) analysis with monoclonal antibodies directed to VSV M protein. Evidence for biological activity of the plasmid-expressed wild-type M protein was provided by marker rescue of the M gene temperature-sensitive mutant tsO23(III) at the restrictive temperature. Somewhat higher levels of M protein expression were obtained in CV-1 cells coinfected with a vaccinia virus-M gene recombinant under control of the T7 polymerase promoter along with T7 polymerase-expressing vaccinia virus vTF1-6,2.     

构建基于杆状病毒的BV-T7杂合表达体系及利用其在哺乳动物和禽类细胞中表达eGFP基因

【目的】研究重组杆状病毒BV-T7杂合表达体系能否有效转导禽类细胞并在禽类细胞中表达外源基因(eGFP),从而构建能在禽类细胞中高效稳定表达外源基因的重组杆状病毒表达系统。【方法】本研究利用Bac-to-Bac杆状病毒表达系统,结合T7表达系统,通过对eGFP表达水平的调控来把握噬菌体T7 RNA聚合酶(T7 RNAP)的功能。利用两支重组杆状病毒,pFastBac-CMV-T7 RNAP重组杆状病毒为哺乳动物细胞启动子CMV调控的噬菌体T7 RNA聚合酶的cDNA;pFB-T7pro-IRES-GFP-T7ter重组杆状病毒为T7启动子控制的eGFP报告基因。将两支重组杆状病毒共同侵染哺乳动物OL(oligodendrocyte)细胞、鸡胚成纤维细胞和鸡胚骨骼肌细胞。【结果】两支重组杆状病毒利用T7启动子和T7 RNAP,在OL细胞、鸡胚成纤维细胞和鸡胚骨骼肌细胞中成功表达eGFP报告基因,而且未引起细胞病变,但在鸡胚原代细胞中eGFP的表达相对弱于在OL细胞中的表达。在OL细胞中重组杆状病毒对细胞的转导效率为59.5%,在鸡胚成纤维细胞和鸡胚骨骼肌细胞中转导效率分别为23.2%和33.1%。【结论】本研究构建的基于杆状病毒、T7RNA聚合酶、T7启动子(BV-T7)杂合表达体系能够在哺乳类细胞及禽类细胞中表达T7 RNAP,并利用T7RNAP继续高效而稳定地表达外源基因。这为难于体外操作的RNA病毒提供了有效的研究方法,并对新型基因工程疫苗的研制提供了一个高效而稳定的表达载体系统。     

鸭白介素-18基因重组真核表达载体的构建及其表达产物的生物学活性

从克隆质柱pGEM-DuIL-18扩增出鸭IL-18全基因片段,克隆到真核表达载体pcDNA3.1( )中,构建重组质粒pcDNA3.1/DuIL-18(简称pDuIL-18).将重组质粒pDuIL-18转染Cos7细胞,转染细胞中含鸭IL-18基因的mRNA.SDS-PAGE分析表明,表达产物是与鸭IL-18相符的约23 000的蛋白条带.鸭淋巴细胞转化试验表明,表达产物对鸭淋巴细胞具有明显诱导转化作用.重组质柱pDuIL-18对H<,9>亚型禽流感灭活疫苗免疫增强作用的研究表明重组质粒pDuIL-18能够提高禽流感灭活疫苗诱发的细胞免疫应答,为研究能够更好地防制禽流感的新型疫苗提供了新的思路.     

Immune potential of a novel multiple-epitope vaccine to FMDV type Asia 1 in guinea pigs and sheep

To develop a safe and efficient recombinant subunit vaccine to foot-and-mouth disease virus(FMDV)type Asia 1 in sheep,a tandem repeated multiple-epitope gene consisting of residues 137-160 and 197-211 of the VP1 gene of FMDV was designed and artificially synthesized.The biologically functional molecule,the ovine IgG heavy constant region(oIgG)as a protein carrier was introduced for design of the multiple-epitope recombinant vaccine and recombinant expression plasmids pET-30a-RE and pET-30a-RE-oIgG were successfully constructed.The recombinant proteins,RE and RE-oIgG,were expressed as a formation of inclusion bodies in E.coli.The immune potential of this vaccine regime in guinea pigs and sheep was evaluated.The results showed that IgG could significantly enhance the immune potential of antigenic epitopes.The recombinant protein RE-oIgG could not only elicit the high levels of neutralizing antibodies and lymphocytes proliferation responses in the vaccinated guinea pigs,but confer complete protection in guinea pigs against virus challenge.Although the recombinant protein RE could not confer protection in the vaccinated animals,it could delay the appearance of the clinical signs and reduce the severity of disease.Inspiringly,the titers of anti-FMDV neutralizing antibodies elicited in sheep vaccinated with RE-oIgG was significantly higher than that for the RE vaccination.Therefore,we speculated that this vaccine formulation may be a promising strategy for designing a novel vaccine against FMDV in the future.     

Overexpression of cloned genes using recombinant Escherichia coli regulated by a T7 promoter: I. Batch cultures and kinetic modeling

A novel Eschericha coli expression system directed by bacteriophage T7 RNA Polymerase utilized for overexpression of the cloned gene. The recombinant cell contains the plasmid with a bacteriophage promoter, the T7 promoter, to regulate the expression of the target gene. This promoter is recongnized only by T7 RNA polymerase, whose gene has been fused into the host chromosome and is under control of the lacUV5 promoter. Therefore, the target gene on the plasmid can be expressed only in the presence of T7 RNA polymerase, which is induced by isopropyl-beta-D-thiogalactopyranoside (IPTG). The batch cultures were performed to investigate the effect of induction on kinetics of cell growth and foreign protein formation and to determine the optimal induction strategy. It was observed that the specific growth rates of the recombinant cells dramatically decrease after induction, and that there is an optimal induction time for maximizing the accumulated intracellular foreign protein. This optimal induction time varies singificantly with inducer concentration. To better understand the optimal behavior, a lumped mechanistic model was constructed to analyze the induced cell growth and foreign protein formation rates. (c) 1992 John Wiley & Sons, Inc.     

Computational modeling of the immune response to tumor antigens

Vaccination protocols designed to elicit anti-cancer immune responses have, many times, failed in producing tumor eradication and in prolonging patient survival. Usually in cancer vaccination, epitopes from one organism are included in the genome or linked with some protein of another in the hope that the immunogenic properties of the latter will boost an immune response to the former. However, recent results have demonstrated that injections of two different vectors encoding the same recombinant antigen generate high levels of specific immunity. Systematic comparison of the efficacy of different vaccination protocols has been hampered by technical limitations, and clear evidence that the use of multiple vectors has advantages over single carrier injections is lacking. We used a computational model to investigate the dynamics of the immune response to different anti-cancer vaccines based on randomly generated antigen/carrier compounds. The computer model was adapted for simulations to this new area in immunology research and carefully validated to the purpose. As a matter of fact, it reproduces a relevant number of experimental observations. The model shows that when priming and boosting with the same construct, competition rather than cooperation develops amongst T cell clones of different specificities. Moreover, from the simulations, it appears that the sequential use of multiple carriers may generate more robust anti-tumor immune responses and may lead to effective tumor eradication in a higher percentage of cases. Our results provide a rational background for the design of novel strategies for the achievement of immune control of cancer.